Bispecific antibody therapy of lymphoid malignancy conditions

• Main Authors: SUN JUNG-HOON, ZHU DAN, HADIVASILIOU, HELENE, CAO HANQING, ACHARYA SANJAY, HARIHARAN KARTHIK, JOHANSEN JAN
• Format: Patent
• Language: Chinese; English
• Published: 01.09.2023
• Subjects: CHEMISTRY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

There is provided a method for treating a lymphoid malignancy in a subject in need thereof, the method comprising administering to the subject an effective amount of a bispecific antibody comprising a Fab moiety that binds to CD47 and a Fab moiety that binds to CD20. In some embodiments, the lymphatic malignancies are non-Hodgkin's lymphoma (NHL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), marginal region lymphoma (MZL), mantle cell lymphoma (MCL), or primary mediastinal B-cell lymphoma. In certain embodiments, the lymphoid malignancy is NHL. 提供了一种用于治疗有需要的受试者的淋巴恶性肿瘤的方法，所述方法包括向所述受试者施用有效量的双特异性抗体，所述双特异性抗体包括与CD47结合的Fab部分和与CD20结合的Fab部分。在一些实施例中，所述淋巴恶性肿瘤是非霍奇金氏淋巴瘤(NHL)、滤泡性淋巴瘤(FL)、弥漫性大B细胞淋巴瘤(DLBCL)、边缘区淋巴瘤(MZL)、套细胞淋巴瘤(MCL)或原发性纵隔B细胞淋巴瘤。在某些实施例中，所述淋巴恶性肿瘤是NHL。